Overview

A Phase II Study of UCN-01 in Metastatic Melanoma

Status:
Terminated

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. This phase II trial is studying how well UCN-01 works in treating patients with metastatic melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

7-hydroxystaurosporine
Staurosporine